Why the study?
Does anti-factor Xa correlate better with heparin dose than ACT in neonates on venoarterial ECMO?
Does anti-factor Xa correlate better with heparin dose than ACT in neonates on venoarterial ECMO?
In neonates on venoarterial ECMO, anti-factor Xa levels correlate significantly with heparin dose, whereas ACT is not a reliable indicator of heparin effect.
Answers are grounded in this paper and cite their sources.
Anti-Xa may better guide heparin dosing than ACT in neonatal VA-ECMO; hypothesis-generating and requires prospective validation.
We studied 12 consecutive neonates placed on venoarterial extracorporeal membrane oxygenation (ECMO) in 2004-2005. Activated clotting times (ACT) and anti-factor Xa levels were measured, and the corresponding heparin drip rate was noted. The mean heparin drip rate was 42.2 +/- 10.9 (SD) U/kg/hour (range 20.0-69.5 U/kg/hour). There were 55 simultaneous ACT and anti-factor Xa samples drawn. The mean ACT was 167 +/- 20 seconds (range 128-227 seconds). There was no correlation between ACT levels and heparin dose (r = 0.21; p = 0.12). The mean anti-factor Xa activities were 0.73 +/- 0.19 U/ml (range 0.1-1.0 U/ml). There was a correlation (r = 0.75; p < 0.0001) between anti-factor Xa and heparin dose. We also examined the effect of day on ECMO on heparin drip rate, ACT, and anti-factor Xa. There was no correlation between day on ECMO and either heparin drip rate (r = 0.21, p = 0.12) or ACT (r = 0.002, p = 0.99). However, there was a positive correlation (r = 0.46, p < 0.0005) between day on ECMO and anti-factor Xa activities. In these neonatal patients on venoarterial ECMO, ACT was not a reliable indicator of heparin effect. Furthermore, the increase in anti-factor Xa levels with time on ECMO suggests that heparin accumulates and/or that anti-thrombin III levels decrease with time on ECMO.
No takes yet. Share an insight, caveat, or question.
Nankervis et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: